|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
|
|---|---|---|---|---|---|---|
| Cash | ||||||
| Prepaid expenses | ||||||
| Total current assets | ||||||
| Deferred offering costs associated with proposed public offering | ||||||
| Investments held in Trust Account | ||||||
| Total Assets | ||||||
| Accounts payable | ||||||
| Accrued expenses | ||||||
| Accrued expenses - related parties | ||||||
| Note payable - related party | ||||||
| Due to related party | ||||||
| Total current liabilities | ||||||
| Deferred underwriting commissions | ||||||
| Total Liabilities | ||||||
| Ordinary shares, $0.0001 par value; 550,000,000 shares authorized; 30,015,000 and 30,015,000 shares subject to possible redemption at $10.46 and $10.28 per share as of June 30, 2026 and December 31, 2025, respectively | ||||||
| Ordinary shares, $0.0001 par value; 550,000,000 shares authorized; 7,503,750 non-redeemable shares issued and outstanding as of June 30, 2026 and December 31, 2025 | ||||||
| Additional paid-in capital | ||||||
| Accumulated deficit | ||||||
| Total shareholders’ deficit | ||||||
| Total Liabilities, Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit |
Loading...
